NCT05551247

Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

A Prospective, Single-arm, Multicenter Clinical Trial of Envafolimab Combined With Recombinant Human Endostatin (Endostatin) in the Treatment of Recurrent or Metastatic MSS-type Colorectal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The objective is to investigate the efficacy and safety of envafolimab combined with recombinant human endostatin (endostatin) in the treatment of MSS-type colorectal cancer patients with recurrence or metastasis after failure of second-line standard therapy.

Detailed description

This study is a multicenter, prospective, single-arm clinical study. That is, eligible colorectal cancer patients, after signing the informed consent form, are screened into the group, and will receive continuous intravenous infusion of envafolimab (envafolimab) combined with recombinant human endostatin (endostatin) until the disease. Progressive or intolerable.

Conditions

• Colorectal Neoplasms

Interventions

Type	Name	Description
DRUG	Envafolimab	300mg,sc,d3,Q3W;
DRUG	recombinant human endostatin (endostatin)	210mg,civ,d1-3,Q3W

Timeline

• Start date: 2022-09-15
• Primary completion: 2023-06-28
• Completion: 2024-06-28
• First posted: 2022-09-22
• Last updated: 2022-09-22